Post-transcriptional control of NLRP3 inflammasome activation in colonic macrophages

Alessandra A. Filardy[1], **Jianping He**[1], **Jack Bennink**[2], **Jonathan Yewdell**[2], and **Brian L. Kelsall**[1]

[1]Mucosal Immunobiology Section, Laboratory of Molecular Immunology, NIAID, NIH, Bethesda, MD 20892

[2]Cellular Biology and Viral Immunology Sections, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD 20892

Abstract

Colonic macrophages (cMPs) are important for intestinal homeostasis as they kill microbes yet produce regulatory cytokines. Activity of the NLRP3 inflammasome, a major sensor of stress and microorganisms that results in pro-inflammatory cytokine production and cell death must be tightly controlled in the intestine. We demonstrate that resident cMPs are hyporesponsive to NLRP3 inflammasome activation due to a remarkable level of post-transcriptional control of NLRP3 and proIL-1β protein expression, which was also seen for TNF-α and IL-6, but lost during experimental colitis. Resident cMPs rapidly degraded NLRP3 and proIL-1β proteins by the ubiquitin/proteasome system. Finally, blocking IL-10R-signaling *in vivo* enhanced NLRP3 and proIL-1β protein, but not mRNA levels in resident cMPs implicating a role for IL-10 in environmental conditioning of cMPs. These data are the first to show dramatic post-transcriptional control of inflammatory cytokine production by a relevant tissue-derived macrophage population and proteasomal degradation of proIL-1β and NLRP3 as a mechanism to control inflammasome activation; findings which have broad implications for our understanding of intestinal and systemic inflammatory diseases.

INTRODUCTION

The immune system in the intestine is required to maintain a symbiotic relationship with commensal bacteria while allowing host-defense against pathogens. Indeed, abnormal immune responses to commensal bacteria that occur in a genetically susceptible host results in Intestinal Bowel Diseases (IBD). Intestinal macrophages are essential for maintaining

Correspondence: Brian L. Kelsall, MD, Laboratory of Molecular Immunology, NIAID, NIH, 10/11N113, 10 Center Drive, MSC 1886, Bethesda, MD 20892-1890, Phone number: 301-496-7473, Fax number: 301-480-6768, bkelsall@niaid.nih.gov.

DISCLOSURE

The authors declare no conflict of interest.

immune homeostasis because of their efficient killing of invading bacteria and production of regulatory cytokines, which, in turn, support the expansion and/or survival of regulatory T cell populations and inhibit the infiltration and activation of inflammatory cells. As was recently shown in mice, circulating monocytes differentiate into predominantly colonic macrophages (cMPs) that produce high levels of inhibitory cytokines in the steady-state but pro-inflammatory molecules during inflammation leading to cell death and tissue damage [1–4] The environmental factors that control the differentiation of monocytes into regulatory cMPs or inflammatory monocytes and cMPs are not yet clear, although IL-10 signaling appears to have a major role [5,6]. Furthermore, the mechanisms that control the activation of pro-inflammatory pathways by intestinal macrophages are poorly understood, and studies to date have focused largely on transcriptional regulation by identifying gene-specific transcription factors as well as enhancer landscapes in macrophages from different tissues including the small intestine and colon [7].

Recent evidence indicates that inflammasome activation needs to be tightly controlled in the intestine. NLRP3 and NLRC4 inflammasomes are multi-component intracellular pattern-recognition receptors (PRRs) from the Nod-like receptors (NLR)-family of proteins [8]. Two signals are required for inflammasome induced IL-1β secretion; one signal from Toll-like receptors (TLR) or other PRRs that results in NF-κB–dependent transcription and translation of proIL-1β and NLRP3, but not NLRC4, which is constitutively expressed; and a second signal that triggers oligomerization of NLRP3 or NLRC4, together with the adaptor protein ASC and procaspase-1 leading to caspase-1 activation and IL-1β cleavage and release from proIL-1β. NLRP3 is activated by numerous host and pathogen-derived factors indicative of stress and injury such as extracellular ATP, while NLRC4 is activated by intracellular products from pathogenic microbes, including flagellin. Both NLRP3 and NLRC4 inflammasome activation, as well as IL-1β and IL-18 are important for colitis development in mouse models of IBD [9,10], and in patients with Crohn's disease, levels of IL-1β and IL-18 are highly elevated in inflamed tissues [11–14], however, the mechanisms by which inflammasomes are regulated are incompletely understood.

Here, we found that resident cMPs are hyporesponsive to NLRP3 inflammasome activation due to a remarkable level of post-transcriptional control of NLRP3 and proIL-1β protein expression. In homeostatic conditions, resident cMPs expressed high levels of mRNA but low levels of protein for NLRP3 and proIL-1β both before and after exposure to TLR agonists and were hyporesponsive to NLRP3 activation. This posttranscriptional control was lost during experimental colitis, where cMPs expressed high NLRP3 inflammasome activity. These results show that micro-environmental signals present in steady-state but not inflammatory conditions orchestrate post-transcriptional control of inflammasome activation in resident cMPs. Furthermore, we demonstrated that resident cMPs rapidly degraded NLRP3 and proIL-1β proteins by the ubiquitin/proteasome system and provided evidence supporting a role for of IL-10 in this process. These findings demonstrate a new level of control of cMPs function important for maintaining immunological homeostasis and have broad implications for our understanding of intestinal and systemic inflammatory diseases.

RESULTS

Resident colonic macrophages are hyporesponsive to NLRP3 and NLRC4 inflammasome activation

To address NLRP3 inflammasome function, resident cMPs were purified by FACS based on the expression of MHC II, F4/80 and CD64 (Supplementary Figure S1a). cMPs, bone marrow–derived macrophages (BMDMs), and peritoneal macrophages (pMPs) were treated with lipopolysaccharide (LPS; TLR4 agonist) and Pam3Cys-Ser-(Lys)4 (P3C4;TLR1/2 agonist) for 4 hours followed by activation for 1 hour with ATP or nigericin. We found that resident cMPs produced markedly less IL-1β when compared to either BMDMs or pMPs following TLR treatment and NLRP3 activation (Figure 1a, b). Immunoblotting for mature IL-1β confirmed poor activation of NLRP3 in resident cMPs (Supplementary Figure S1b). We chose the combination of two common TLR agonists since it is likely that cMPs are exposed to multiple bacterial ligands in the colon, and because prior studies suggested cMPs respond poorly to LPS [15,16]. We confirmed that adding P3C4 had no untoward effects on inflammasome induction or activation since both LPS or LPS/P3C4 and ATP induced similar levels of IL-1β secretion from cMPs and BMDMs (Supplementary Figure S1c). Finally, to determine the NLR-specificity of these effects, we also measured IL-1β production following the activation of NLRC4. Similar to NLRP3, cMPs but not BMDMs produced low levels of IL-1β following NLRC4 activation (Figure 1b and Supplementary Figure S1b).

NLRP3 and proIL-1β protein expression are post-transcriptionally regulated in resident colonic macrophages

We next addressed the possibility that poor NLRP3 inflammasome activity in resident cMPs was due to decreased TLR signaling [15,16] resulting in poor transcription of *NLRP3* and *IL-1β* genes. Consistent with published data [17], mRNA for both NLRP3 and proIL-1β was undetectable in unstimulated BMDMs, however, we found very high levels of mRNA for NLRP3 and proIL-1β in unstimulated resident cMPs. In contrast, mRNA for ASC was expressed at similar levels in both BMDMs and cMPs (Figure 2a). TLR stimulation further enhanced expression of mRNA for proIL-1β and NLRP3 in resident cMPs to levels similar to, or higher than those induced in BMDMs, respectively (Figure 2a). Therefore, low NLRP3 inflammasome activity in resident cMPs was not simply due to low levels of gene transcription following TLR signaling.

Importantly, however, despite very high levels of mRNA for proIL-1β and NLRP3, protein levels were low or undetectable in resident cMPs either before or after TLR stimulation (Figure 2b). This finding contrasted dramatically with BMDMs for which both mRNA and protein levels of NLRP3 and proIL-1β were significantly induced by TLR activation. Furthermore, TNF-α and IL-6 were regulated in a similar manner to NLRP3 and proIL-1β in cMPs, but in contrast, IL-10 was expressed in high levels for both mRNA and protein in resident cMPs before and after TLR stimulation compared to BMDMs (Figure 2c, d). Resident cMPs and BMDMs expressed similar levels of procaspase-1 and ASC proteins.

These data strongly suggested that NLRP3 inflammasome activity in cMPs is controlled by post-transcriptional mechanisms that limit the accumulation of NLRP3 and proIL-1β protein in steady-state conditions. The low expression of proIL-1β observed in cMPs could explain why NLRC4 stimulation did not result in high levels of IL-1β release. Our results also demonstrated that in a relevant tissue-specific cell-type post-transcriptional control could apply to the regulation of TNF-α, and possibly IL-6 [18–21] expression with gene specificity, as there was less effect on IL-10, procaspase-1 and ASC.

Colonic macrophages isolated from mice with colitis are responsive to NLRP3 inflammasome activation

The intestinal lamina propria macrophage compartment is dependent on continuous recruitment of Ly6C[+] monocytes[1–4]. Since blood monocytes are fully responsive to NLRP3 activation [22], the maturation of unresponsive resident cMPs is likely driven by the factors in the intestinal microenvironment in the steady-state, and such conditioning may be altered during inflammation. To address this question, we evaluated cMPs in RAG-deficient mice with colitis following adoptive transfer of naive CD4[+]CD45RB[hi]CD25[−] T cells [23]. In contrast to resident cMPs from uninflamed mice, MHCII[hi]F4/80[+]CD64[+] inflammatory monocytes and cMPs (infl. mono./cMPs) from mice with colitis secreted high levels of mature IL-1β after NLRP3 or NLRC4 activation (Figure 3a), consistent with their constitutive and TLR-inducible expression of NLRP3 and proIL-1β protein (Figure 3b). In addition, similar to resident cMPs, infl. mono./cMPs expressed higher levels of NLRP3 and proIL-1β mRNA than BMDMs under resting condition, but expressed much higher proIL-1β protein expression than resident cMPs (Figure 3c, d and Supplementary Figure S2a). Furthermore, MHCII[hi]F4/80[+]CD64[+]Ly6C[lo/−] cMPs population that lack Ly6C[+] inflammatory monocytes (Supplementary Figure S2b), exhibited the same enhancement in NLRP3 and proIL-1β protein expression in colitic mice as seen with total MHCII[hi]F4/80[+]CD64[+] cells (Figure 3e), indicating that monocytes that mature into cMPs in the setting of inflammation retain enhanced inflammasome activity. Of note, immublots of cMPs from non-colitic RAG-deficient mice revealed a discrete proIL-1β band (Figure 3e) that was undetectable in cMPs from WT B6 mice (Figure 1b and Supplementary figure 2a). The reason for this discrepancy is not yet clear, however, it is possible that B cells or Tregs may contribute to post-transcriptional control, which is lacking in non-colitic RAG-deficient mice. Despite the discrepancy in baseline proIL-1β levels, a major difference in the levels of proIL-1β was still present between cMPs from colitic and non-colitic mice. Finally, although infl. mono./cMPs retain the ability to secrete high levels of the anti-inflammatory cytokine IL-10 (Figure 3f), they produced robust levels of TNF-α (Figure 3g), suggesting a more general lack of post-transcriptional control of pro-inflammatory cytokine production by monocyte-derived cells under inflammatory conditions.

NLRP3 and proIL-1β protein expression is regulated by proteasomal degradation in resident colonic macrophages

Both NLRP3 and proIL-1β may be subject to a number of post-transcriptional regulatory mechanisms [24]. These include the regulation of mRNA splicing, polyadenylation, and stability, as well as control of protein translation and degradation. Recent reports have shown that the functional activity of NLRP3 can be regulated by ubiquitination/deubiquitination,

and that IL-1β protein levels may be controlled by ubiquitination and proteasomal degradation in bone marrow-derived dendritic cells (BMDCs), *in vitro* [25–28]. We first examined whether the low protein levels of NLRP3 and proIL1β in resident cMPs at steady-state were due to rapid degradation by the proteasome. cMPs and BMDMs were treated with MG-132, a specific and efficient proteasome inhibitor [29–32]. Since MG-132 will suppress NF-κB activation that is dependent on proteasomal degradation of IκB, cMPs and BMDMs were stimulated with LPS/P3C4 for 3 hours prior to the addition of MG-132 for 1 hour. Blocking proteasome activity with MG-132 significantly increased the protein levels of NLRP3 and proIL-1β in resident cMPs but not in BMDMs, while neither ASC, nor procaspase-1 protein expression was affected in either cell population (Figure 4a). Similarly, cMPs treated with MG-132 in the absence of LPS/P3C4 pre-treatment produced higher levels of NLRP3 and proIL-1β (Supplementary Figure S4). These data are the first to indicate that NLRP3 levels may be controlled via the ubiquitin-proteasome system, and show proteasome-dependent suppression of IL-1β production in a relevant tissue-derived cell population.

IL-10 has a role in regulating NLRP3 and proIL-1β protein expression in resident colonic macrophages

The role of IL-10 signaling in maintaining immune homeostasis in the intestinal mucosa through the downregulation of pro-inflammatory responses to bacterial products is well established [5,633,34]. Therefore, we explored whether IL-10 signaling in resident cMPs could contribute to the post-transcriptional control of NLRP3 and proIL-1β protein expression levels in resident cMPs. MHCII^{hi}F4/80$^+$CD64$^+$ cMPs sorted from IL-10$^{-/-}$ mice before the onset of colitis [as indicated by the low numbers of Ly6C$^+$ inflammatory monocytes in their colon tissue (Supplementary Figure S3a)] indeed had significantly higher levels of NLRP3 and proIL-1β protein in comparison to cMPs from WT mice (Figure 4b left panel), while their mRNA levels were not significantly elevated in comparison to IL-10 sufficient WT control mice (Figure 4c). These results were confirmed with cMPs from mice that received neutralizing anti-IL-10R antibodies for 11 days (Supplementary Figure S3b, Figure 4b middle panel and Figure 4c). To further rule out the possibility that underlying inflammation in mice lacking IL-10 or IL-10 receptor (IL-10R)-signaling, was responsible for these findings we generated mixed bone-marrow chimeric mice (WT:IL-10RB$^{-/-}$ 1:1), and analyzed the levels of proIL-1β and NLRP3 protein in IL-10RB$^{-/-}$MHCII^{hi}F4/80$^+$CD64$^+$Ly6C$^{lo/-}$ resident cMPs (Supplementary Figure S3c). Consistently we found that IL-10 is involved in the post-transcriptional regulation of NLRP3 and proIL-1β protein expressions in resident cMPs (Figure 4b right panel), which is not dependent on the presence of inflammation. Collectively, these results suggest that IL-10 has a role in regulating inflammasome activation in resident cMPs at the post-transcriptional level, however, whether this effect on cMPs is direct or indirect is not yet clear.

DISCUSSION

The data presented here demonstrate for the first time that inflammasome activation and cytokine production by resident cMPs are controlled by post-transcriptional mechanisms that are highly selective for certain genes and dependent on specific local environmental

conditions in the intestine. Post-transcriptional control of NLRP3 and proIL-1β, in addition to TNF-α and IL-6, in resident cMPs may contribute to the maintenance of immune homeostasis in colon in the steady-state, since the activation of the NLRP3 inflammasome by microbial products (including LPS and ATP) induces not only the secretion of the pro-inflammatory cytokines IL-1β and IL-18, but also pyroptosis, a pro-inflammatory cell death program, uniquely dependent on caspase-1. We hypothesize that post-transcriptional regulation of NLRP3, proIL-1β, TNF-α and IL-6, in resident cMPs represents a mechanism to maintain intestinal homeostasis during constant exposure to commensal microbiota, yet poise these cells for rapid inflammatory cytokine production from high internal stores of mRNA in response to invading pathogens, through as yet unidentified signals. Furthermore, while it is still unknown if resident cMPs are plastic and change their phenotype during initial stages of colitis induction, the current data also indicate that cMPs derived from circulating monocytes recruited during active inflammation have lost their capacity to regulate NLRP3 and proIL-1β as well as TNF-α and IL-6 through post-transcriptional control which likely contributes to chronic inflammation.

The release of IL-1β was impaired after NLRP3 inflammasome activation in highly purified resident cMPs. Although resident cMPs expressed high levels of mRNA for all NLRP3 inflammasome components, they expressed low to undetectable levels of proIL1β and NLRP3. In addition to the lack of the NLRP3 substrate proIL-1β, stimulation of NLRP3 failed to result in the activation of caspase-1 in cMPs, indicating upstream effects on inflammasome activation that were most likely due to the low expression of NLRP3. Low levels of proIL-1β may also explain the low IL-1β release following NLRC4 activation in cMPs. Whether NLRC4 protein levels are also post-transcriptionally regulated is not yet clear, as we were unable to detect NLRC4 protein by immunoblots with currently available antibodies. Furthermore, our data using highly purified cMPs are not necessarily inconsistent with a previous report showing that lack of signaling through NLRP3 but not NLRC4 in intestinal CD11b[+] phagocytes which may facilitate the discrimination of commensal and pathogenic bacteria [35]. The CD11b[+] population studied in this report contained 20–30% F4/80[−] cells that may include DCs and IgA[+] plasma cells [36] which may maintain NLRC4 activity in the intestinal environment. Studies of other cell populations will be important future studies.

One important conclusion from the current data is that levels of mRNA in cMPs (and possibly other intestinal cell types) do not correlate with protein expression for a number of cytokines thought to be essential for intestinal inflammation. These data are important for directing future studies, and also indicate a need for reinterpreting prior experiments with rare tissue cells that relied on mRNA analysis as the only measure of gene expression, and on which new hypotheses and research questions have been based.

The current findings also indicate for the first time, that in addition to proIL-1β, NLRP3 levels can be controlled via the ubiquitin-proteasome system. Recent reports have shown that both proIL-1β and NLRP3 are polyubiquitinated in primary cells *in vitro*, but that ubiquitination results in several possible outcomes. Thus, following *in vitro* activation of murine BMDCs and BMDMs with TLR ligands, proIL-1β, after initial induction was polyubiquitinated and progressive degraded over time, possibly as a mechanism to control

its release in the setting of continued inflammasome activation [25]. In contrast, others have shown that in BMDMs, proIL-1β is constitutively ubiquitinated (likely by the addition of K63-linked and unanchored polyubiquitin to the proIL1β complex) which enhances proIL-1β interaction with procaspase-1, and thus increasing NLRP3 activity in these cells [28]. Furthermore, it has also been reported that in BMDMs constitutive polyubiquitination of NLRP3 inhibits its activity (rather than by inducing its degradation), and that deubiquitination following TLR or ATP activation results in enhanced activation [26,27]. In the present study, we demonstrated that the inhibition of proteasome activity by MG-132 significantly increased the protein levels of both NLRP3 and proIL-1β in resident cMPs but displayed no effect in BMDMs. Because the effects of MG-132 on the proteasome are highly specific [29–32], and MG-132 is now accepted as a highly effective way to block proteasome activity, we believe the current data are the first to indicate the role of the ubiquitin/proteasome system in the degradation of both NLRP3 and proIL-1β as a mechanism to control inflammasome activation *in vivo*, and in a relevant tissue-specific cell population, the intestinal macrophage. While a direct demonstration of NLRP3 and proIL-1β ubiquitination in cMPs by immunoprecipitation and immunoblotting would affirm these conclusions, these experiments are practically impossible, as they require $5–10 \times 10^6$ cells per condition, which for purified cMPs would require (including controls) colon tissue from at least 500 mice per experiment. Therefore, we are currently exploring the possibility of conditioning BMDMs or cell lines in vitro to mimic our findings in cMPs to allow for further confirmation of direct ubiquitination.

IL-10-signaling of cMPs likely plays an important role in maintaining immune homeostasis in the intestine as deletion of the IL-10R in CX3CR1[+] or lysozyme-expressing cells that include resident cMPs, results in pro-inflammatory responses to bacterial products and spontaneous colitis [5,6], similar to IL-10R deficient humans with severe IBD [33,34]. IL-10 and downstream IL-10R signaling are important to control the activation of mucosal T cells [37–39] as well as innate cells like DCs and macrophages [5]. Furthermore, cMPs are a major source of IL-10 in the intestine [5], and IL-10 production is not highly controlled by post-transcriptional mechanisms, as shown here. Therefore, we determined whether IL-10 may be involved in post-transcriptional control of inflammatory cytokines *in vivo*. We found that resident cMPs isolated from IL-10[−/−] mice, or mice treated with neutralizing anti-IL-10R antibodies, before the onset of colitis had significantly increased expression of NLRP3 and proIL-1β protein in comparison to cMPs from untreated WT mice. Since the absence of IL-10 in the intestinal environment can cause inflammation and the recruitment of inflammatory monocytes to the intestinal tissue[5,33,40], which are fully responsive to NLRP3 activation [22], we confirmed these findings in resident cMPs (Ly6C[lo/−]) from mixed IL-10RB[−/−] x WT bone-marrow chimeric mice without inflammation. Together these results indicated that IL-10 contributes to the post-transcriptional regulation of NLRP3 and proIL-1β protein expression in resident cMPs. However, whether IL-10 acts directly on cMPs to control NLRP3 and proIL-1β expression or indirectly through effects on other cell types remains unclear, as experiments to address this issue are currently impractical due to high costs (e.g., IL-10[−/−] mice to perform IL-10 add-back experiments on purified cMPs) or poor specificity of conditional knockout mice for cMPs. Furthermore, given that the protein levels seen in IL-10-signaling deficient cells were still low compared to levels seen in TLR-

stimulated BMDMs with a similar level of mRNA, additional environmental factors are certainly involved.

At present, we have no evidence for additional post-transcriptional control mechanisms for NLRP3 or proIL-1β, and have not yet addressed the mechanisms regulating TNF-α or IL-6 in resident cMPs. For example, we have no definitive evidence for splice variants of NLRP3, proIL-β or other cytokines, and since levels of mRNA are high, increased mRNA degradation does not appear to account for low protein levels. In this regard, miR223, which can suppress NLRP3 expression and activation in BMDMs [41] by inhibiting mRNA accumulation is not likely involved in the current effects, despite its high levels of in cMPs (data not shown). Inhibition of translation could certainly contribute to the poor protein production seen in the present studies, in particular for TNF-α, for which IL-10 was shown in *in vitro* studies of thioglycolate-elicited pMPs and BMDMs to block both transcription and translation, but not mRNA stability [18,19] Unfortunately, techniques to analyze mRNA translation for specific genes by ribosome profiling, microarray analysis of mRNA associated with polysomes, or translational profiling through the affinity purification of epitope tagged ribosomes cannot be performed on the small number of cMPs that we can isolate, so at the present time there is no clear method to determine translational efficiencies for NLRP3 and proIL-1β by resident cMPs. Interestingly, IL-6 has been shown to be highly regulated through effects on mRNA stability, but this does not seem to play a primary role in resident cMPs for which IL-6 mRNA levels are exceptionally high [20,21]. Future studies will need to address these issues.

In conclusion, our data demonstrate that NLRP3 inflammasome activation and pro-inflammatory cytokine production by resident cMPs are controlled by post-transcriptional mechanisms that are highly selective for certain genes and dependent on local environmental conditions. These mechanisms likely contribute to immune homeostasis in a constantly challenged intestinal environment, but are lost during intestinal inflammation. While multiple post-transcriptional mechanisms may be involved, our data indicate that the degradation of NLRP3 and proIL-1β proteins by the ubiquitin-proteasome pathway is one such mechanism, and that IL-10 plays a role in steady-state conditioning. Further characterization of post-transcriptional control mechanisms in cMPs should contribute to our understanding of intestinal pathophysiology and may provide new targets for the treatment of patients with IBD.

METHODS

Antibodies and reagents

Ultrapure *Escherichia coli* LPS (K12 strain) and synthetic bacterial lipoprotein Pam3Cys-Ser-(Lys)4 (P3C4) were obtained from Invivogen (San Diego, CA), ATP and nigericin from Sigma-Aldrich (St. Louis, MO). FlaTox, an engineered protein complex containing components of *Bacillus anthracis* toxin (amino-terminal domain of *B. anthracis* lethal factor and anthrax protective antigen channel) that allows cytosolic delivery of *Legionella pneumophila* flagellin or its mutated inactive form (AAA) [42], was a gift from Dr. Russell Vance (University of California, Berkeley, CA). Anti-IL-10R monoclonal antibody (clone 1B1.3a) was a kind gift from David Sacks, NIAID, NIH. Control rat IgG was obtained from

BioXCell (West Lebanon, NH). The proteasome inhibitor MG-132 was from Enzo Life Sciences (Farmingdale, NY). The following antibodies used in the study were: anti-NLRP3/NALP3 mAb (Cryo-2) was obtained from AdipoGen (San Diego, CA), anti-IL-1β from R&D Systems (Minneapolis, MN), anti-ASC (N-15) and anti-caspase-1 p10 (M-20) from Santa Cruz Biotechnology (Dallas, TX), anti-actin from Cell Signaling Technology (Danvers, MA), anti–mouse horseradish peroxidase (HRP), anti–rat IgG HRP, anti-rabbit IgG HRP and anti-goat IgG HRP from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA), Fc block/anti-CD16/32 (2.4G2) and directly conjugated monoclonal antibodies (mAb/clone): anti-CD19/eBio1D3, B220/RA3-6B2, TCR-β/H57-597, TCR-γδ/eBioGL3, MHC II/M5-114.15.2, Ly6C/HK1.4, CD4/GL1.5, CD45RB/M1-70, CD25/PC61.5, CD45.1/A20 and CD45.2/104 used in flow cytometry were from eBioscience (San Diego, CA). Other conjugated mAb (anti-F4/80/BM8 and CD64/X54-5/7.1) were from Biolegend (San Diego, CA).

Mice

All the experiments were performed using C57BL/6 (B6) mice. B6 mice were obtained from the National Cancer Institute and used at 6 – 12 wk of age. *Rag1*$^{-/-}$ mice were purchased from Taconic Farms (Derwood, MD). IL-10$^{-/-}$ and IL-10RB$^{-/-}$ mice were purchased from The Jackson Laboratory (Sacramento, CA). All mice were maintained at an American Association for the Accreditation of Laboratory Animal Care–accredited animal facility at the National Institute of Allergy and Infectious Diseases and housed in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals under an animal study proposal approved by the National Institute of Allergy and Infectious Diseases Animal Care and Use Committee.

Experimental animal models

T cell transfer colitis—Total CD4$^+$ T cells were isolated from the spleens of 6 – 8 wk old female B6 mice via negative selection using the magnetic activation cell sorter (MACS) CD4 T-cell isolation kit (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions. Enriched cells were subsequently sorted for naive CD4$^+$CD25$^-$CD45RB^{high} T cells using FACS (FACSAriaTM, BD Biosciences, San Jose, CA). In all, 3x10^5 CD4$^+$CD25$^-$CD45RB^{high} cells were transferred intraperitoneally (i.p.) to recipient 6 – 8 wk old female *Rag1*$^{-/-}$ mice, which were subsequently housed under SPF non-sterile conditions (nonsterile bedding, nonsterile food and non-acidified water) [23]. The development of intestinal inflammation was monitored by weight loss, which correlates with histological evidence of colitis and increased cell numbers of MHC II^{hi} cells in the colon. The study end point was defined as a mean weight loss of 25–30% from initial weight of *Rag1*$^{-/-}$ mice that usually occurred 6 – 8 wk after adoptive transfer. For each analysis, cells collected and pooled from 20 – 30 animals per experiment.

Neutralization of IL-10 receptor *in vivo*—WT B6 mice were i.p. treated with 3 doses of 0.5 mg/mice of anti-IL-10R monoclonal antibody (1B1.3a) or isotype control/PBS for 11 days. After the treatment, mice were euthanized and colons were removed to obtain purified and FACS sorted cMPs as described bellow.

IL-10RB$^{-/-}$/WT mixed bone marrow chimeric mice—Mixed chimeric mice were generated by reconstituting lethally irradiated (900 rads) WT B6 mice with 3×10^6 total bone marrow cells intravenously (i.v.) isolated from both WT (CD45.1) and IL-10RB$^{-/-}$ (CD45.2) mice (1:1 ratio). B6 bone marrow chimeric mice received drinking water containing antibiotics (0.13 mg/ml Trimethoprim and 0.67 mg/ml Sulfamethoxazole) for 4 wk followed by 4 wk of regular water. Similar percentages of cMPs from chimeric mice were found to be CD45.1 and CD45.2 indicating equivalent engraftment and development of WT and IL-10RB$^{-/-}$ cMPs.

Macrophage isolation, differentiation and activation

cMPs were prepared as described previously [2]. Briefly, entire colons from 30 – 50 mice were collected and washed with calcium and magnesium-free Hanks' balanced salt solution (HBSS; Gibco; Grand Island, NY). The tissues were opened longitudinally, cut into 2-cm pieces and incubated with HBSS containing 0.015% dithiothreitol (DTT; Sigma-Aldrich) for 15 min, followed by extensive washing in cold HBSS containing 5% heat-inactivated fetal bovine serum (FBS; GemCell, West Sacramento, CA) to remove epithelial cells and mucus. Colon pieces were finely minced and digested in complete {supplemented with penicillin-streptomycin, 2 mM L-glutamine, 15 mM HEPES (all from Gibco), 50 μM β-mercaptoethanol (Sigma-Aldrich) and 10% FBS} Iscove's media (Gibco) containing 167 μg/ml Liberase TL and 30 μg/ml DNase I (Roche, Indianapolis, IN) for 60 min at 37°C. The samples were filtered, pelleted and resuspended in 1.077 g/cm3 Optiprep (Axis-Shield, Dundee, Scotland). After centrifugation at 2000 rpm for 15 min at room temperature, the viable cells from the layer surface were collected and cMPs were sorted using FACSAria™ (BD Biosciences). To obtain cMPs, MHCII^{hi}F4/80^{hi}CD64$^+$ cells were sorted. Resident pMPs were obtained by washing the peritoneal cavity of B6 mice with cold HBSS and the resulting cells were sorted for CD19$^-$MHC II^{hi}F4/80^{hi} cells. BMDMs were generated by flushing femurs and tibias with PBS, and precursor cells were cultured in complete RPMI 1640 media (Gibco) supplemented with 30% L929 cell-conditioned medium, as the source of macrophage colony-stimulating factor. After 7 d in culture, mature BMDMs were harvested using CellStripper (CellGro, Pittsburgh, PA).

Inflammasome activation and proteasome inhibition

Sorted cMPs, pMPs or BMDMs in complete RPMI 1640 media were added to 96-well plates (1×10^5 cells per 100 μL) and stimulated with ultrapure LPS (200 ng/mL) and P3C4 (2 μg/mL) for 4h at 37°C followed by ATP (5 mM) or nigericin (10 μM) or FlaTox (3 μg/mL of LFn–FlaA and 6 μg/mL of PA) or mutated Flatox negative control protein (AAA) (3 μg/mL of LFn–FlaAAA and 6 μg/mL of PA) stimulation for 1h at 37°C. In some experiments, cMPs, BMDMs or pMPs were stimulated with ultrapure LPS (200 ng/mL) and P3C4 (2 μg/mL) for 3h at 37°C followed by proteasomal inhibitor MG-132 (5 μM) or an equivalent volume of dimethyl sulfoxide (DMSO; Sigma-Aldrich) treatment for 1h at 37°C.

Measurement of cytokines

Cell culture supernatants were harvested after 5 h of culture in medium alone, or after treatment with LPS/P3C4 or LPS/P3C4 plus inflammasome activators. Mouse cytokines

concentrations were measured by conventional double-sandwich ELISA kits from eBioscience (IL-1β and IL-6) and R&D Systems (TNF-α and IL-10), respectively, according to the manufacturer's instructions.

RNA isolation and real-time RT-PCR

For real-time RT-PCR analysis of gene expression, cMPs and BMDMs were collected and total RNA was isolated using an RNeasy Mini Kit (Qiagen, Valencia, CA) following the manufacturer's instructions. cDNA was synthetized using qScript cDNA Supermix (Quanta, Gaithersburg, MD) and real-time PCR analysis was performed on the 7900HT Fast Real-Time PCR instrument (Applied Biosystems, Grand Island, NY) using FAM-labeled gene-specific probes and primers (Applied Biosystems). The level of target gene expression was calculated as $2^{-\Delta Ct}$ where $\Delta Ct = Ct_{target} - Ct_{GAPDH}$ with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as endogenous control and Ct indicating threshold cycle.

Immunoblotting

Cells were lysed in buffer containing 1% Triton-X (Sigma-Aldrich) supplemented with complete protease inhibitor cocktail (Cell Signaling). For the reduction of samples, NuPAGE sample reducing agent (Invitrogen, Grand Island, NY) was added. Supernatants were precipitated with methanol/chloroform before NLRP3 inflammasome components were analyzed. Lysates or supernatants were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 4–12% Bis-Tris precast mini gels in an X-Cell Sure-Lock Mini-Cell (Novex; Invitrogen) following manufacture's instructions. SDS-PAGE gel proteins were transferred to nitrocellulose membranes by electro-blotting using an iBlot System (Life Technologies, Grand Island, NY). The membranes were immunoblotted with respective antibodies and developed using SuperSignal West Pico chemiluminescent substrate (Thermo Scientific, Waltham, MA). The NIH ImageJ software gel-analysis method was used to quantify immunoblotting bands. The background was subtracted, and the absolute density of each peak is shown as arbitrary units.

Statistical analysis

Except where indicated, all experiments shown are representative of three or more independent experiments with similar results. An unpaired, two-tailed Student's *t* test was performed using Prism 6 software (GraphPad Software, La Jolla, CA). Differences with a value of $p < 0.05$ (*), $p < 0.01$(**) or $p < 0.001$(***) were considered significant.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. Bain CC, et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 2013; 6:498–510. [PubMed: 22990622]

2. Rivollier A, He J, Kole A, Valatas V, Kelsall BL. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J Exp Med. 2012; 209:139–155. [PubMed: 22231304]

3. Tamoutounour S, et al. CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis. Eur J Immunol. 2012; 42:3150–3166. [PubMed: 22936024]

4. Zigmond E, et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity. 2012; 37:1076–1090. [PubMed: 23219392]

5. Shouval DS, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity. 2014; 40:706–719. [PubMed: 24792912]

6. Zigmond E, et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity. 2014; 40:720–733. [PubMed: 24792913]

7. Lavin Y, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 2014; 159:1312–1326. [PubMed: 25480296]

8. Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. 2012; 13:325–332. [PubMed: 22430785]

9. Hu B, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A. 2010; 107:21635–21640. [PubMed: 21118981]

10. Bauer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010; 59:1192–1199. [PubMed: 20442201]

11. Monteleone G, et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol. 1999; 163:143–147. [PubMed: 10384110]

12. Casini-Raggi V, et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol. 1995; 154:2434–2440. [PubMed: 7868909]

13. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease. Gut. 1990; 31:686–689. [PubMed: 2379873]

14. Pizarro TT, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohns disease: expression and localization in intestinal mucosal cells. J Immunol. 1999; 162:6829–6835. [PubMed: 10352304]

15. Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol. 2007; 8:1086–1094. [PubMed: 17873879]

16. Smythies LE, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest. 2005; 115:66–75. [PubMed: 15630445]

17. Bauernfeind FG, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009; 183:787–791. [PubMed: 19570822]

18. Kontoyiannis D, et al. Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology. EMBO J. 2001; 20:3760–3770. [PubMed: 11447117]

19. Smallie T, et al. IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. J Exp Med. 2010; 207:2081–2088. [PubMed: 20805562]

20. Iwasaki H, et al. The IkappaB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat Immunol. 2011; 12:1167–1175. [PubMed: 22037600]

21. Masuda K, et al. Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proc Natl Acad Sci U S A. 2013; 110:9409–9414. [PubMed: 23676272]

22. Guarda G, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 2011; 34:213–223. [PubMed: 21349431]

23. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993; 5:1461–1471. [PubMed: 7903159]

24. Carpenter S, Ricci EP, Mercier BC, Moore MJ, Fitzgerald KA. Post-transcriptional regulation of gene expression in innate immunity. Nat Rev Immunol. 2014; 14:361–376. [PubMed: 24854588]

25. Ainscough JS, et al. Dendritic cell IL-1alpha and IL-1beta are polyubiquitinated and degraded by the proteasome. J Biol Chem. 2014; 289:35582–35592. [PubMed: 25371210]

26. Juliana C, et al. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem. 2012; 287:36617–36622. [PubMed: 22948162]

27. Py BF, Kim MS, Vakifahmetoglu-Norberg H, Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell. 2013; 49:331–338. [PubMed: 23246432]

28. Duong BH, et al. A20 restricts ubiquitination of pro-interleukin-1beta protein complexes and suppresses NLRP3 inflammasome activity. Immunity. 2015; 42:55–67. [PubMed: 25607459]

29. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med (Berl). 2003; 81:235–245. [PubMed: 12700891]

30. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001; 8:739–758. [PubMed: 11514224]

31. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 1998; 8:397–403. [PubMed: 9789328]

32. Moore BS, Eustaquio AS, McGlinchey RP. Advances in and applications of proteasome inhibitors. Curr Opin Chem Biol. 2008; 12:434–440. [PubMed: 18656549]

33. Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B. IL-10 and IL-10 receptor defects in humans. Ann N Y Acad Sci. 2011; 1246:102–107. [PubMed: 22236434]

34. Murugan D, et al. Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantation. J Clin Immunol. 2014; 34:331–339. [PubMed: 24519095]

35. Franchi L, et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol. 2012; 13:449–456. [PubMed: 22484733]

36. Kunisawa J, et al. Microbe-dependent CD11b+ IgA+ plasma cells mediate robust early-phase intestinal IgA responses in mice. Nat Commun. 2013; 4:1772. [PubMed: 23612313]

37. Chaudhry A, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011; 34:566–578. [PubMed: 21511185]

38. Murai M, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol. 2009; 10:1178–1184. [PubMed: 19783988]

39. Huber S, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity. 2011; 34:554–565. [PubMed: 21511184]

40. Glocker EO, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009; 361:2033–2045. [PubMed: 19890111]

41. Bauernfeind F, et al. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol. 2012; 189:4175–4181. [PubMed: 22984082]

42. von Moltke J, et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature. 2012; 490:107–111. [PubMed: 22902502]

Figure 1.
Resident cMPs have poor NLRP3 inflammasome activity. Resident cMPs, BMDMs and pMPs were treated with LPS (200 ng/mL) and P3C4 (2 μg/mL) for 4 hr with and without stimulation for 1 hr with ATP (5 mM), nigericin (10 μM) or Flatox (3 μg/mL of LFn–FlaA and 6 μg/mL of PA). (**a**, **b**) IL-1β measured in culture supernatants by ELISA. Data are from sorted-cells pooled from 30 colons presented as the mean ± SD of two biological replicates, and analyzed using an un-paired, two-tailed Student's *t* test. **, $p < 0.01$; ***, $p < 0.001$; NS, not significant, $p > 0.05$. The data presented are representative of at least three independent experiments with similar results. BMDMs, bone marrow-derived macrophages; cMPs, colonic macrophages; pMPs, peritoneal macrophages; US, unstimulated.

Figure 2.
mRNA and protein levels for inflammasome components. Resident cMPs and BMDMs were treated with LPS (200 ng/mL) and P3C4 (2 μg/mL) for 4 h followed by ATP (5 mM) stimulation for 1 hr. (**a**) mRNA levels for NLRP3, proIL-1β, procaspase-1 and ASC. (**b**) Immunoblots of cell lysates and supernatants. Data are from sorted-cells pooled from 90 colons. (**c**) mRNA levels, and (**d**) protein measured in culture supernatants for TNF-α, IL-6, and IL-10. For **a**, **c** and **d**, data are from sorted-cells pooled from 30 colons and are presented as the mean ± SD of two biological replicates analyzed using an un-paired, two-tailed by a Student's t test, *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; NS, statistically not significant, $p > 0.05$. For **b**, data are from sorted-cells pooled from 90 colons. All experiments shown are representative of at least three independent experiments with similar results. cMPs, colonic macrophages; BMDMs, bone marrow-derived macrophages; US, unstimulated; procasp1, procaspase-1.

Figure 3.
Inflammasome regulation in intestinal myeloid cells from mice with colitis. BMDMs, inflammatory monocytes and cMPs (infl. mono./cMPs; F480$^+$CD64$^+$; colitic $Rag1^{-/-}$ mice) or cMPs (F480$^+$CD64$^+$Ly6C$^{lo/-}$; colitic $Rag1^{-/-}$ mice) and cMPs (F480$^+$CD64$^+$Ly6C$^{lo/-}$; non-colitic $Rag1^{-/-}$ mice) from uninflamed mice were treated with LPS (200 ng/mL) and P3C4 (2 μg/mL) for 4 h with or without stimulation with ATP (5 mM), nigericin (10 μM), Flatox (3 μg/mL of LFn–FlaA and 6 μg/mL of PA), or mutated Flatox negative control protein (AAA) (3 μg/mL of LFn–FlaAAA and 6 μg/mL of PA) for 1 hr. (**a**) IL-1β measured in culture supernatants. (**b**) Immunoblot for NLRP3 inflammasome components performed on cell lysates. (**c**) mRNA levels for NLRP3 and (**d**) proIL-1β from BMDMs and infl. mono./cMPs. (**e**) Immunoblot of inflammasome components from F480$^+$CD64$^+$Ly6C$^{lo/-}$ cMPs from uninflamed and inflamed $Rag1^{-/-}$ mice. (**f**) IL-10 and (**g**) TNF-α protein in culture supernatants from infl. mono./cMPs and BMDMs. Results for (**a**, **c**, **d**, **f** and **g**) are from sorted-cells pooled from 10–20 (infl. mono./cMPs) or 30 (cMPs) colons and are presented as the mean ± SD of two biological replicates analyzed using an un-paired, two-tailed by a Student's t test. *, $p < 0.05$; **, $p < 0.01$; NS, statistically not significant, $p > 0.05$. Results for (**b**) are from sorted-cells pooled from 160 or (**e**) 30–40 mice. All the data are representative of at least 3 independent experiments with similar results. US, unstimulated; OE, overexposed.

Figure 4.
Regulation of NLRP3 and proIL-1β protein expression by proteasomal degradation and IL-10. (**a**) Resident cMPs from WT mice and BMDMs were pretreated with LPS (200 ng/mL) and P3C4 (2 μg/mL) for 3 hr followed by 1 hr of treatment with the proteasome inhibitor MG-132 (5 μM), or an equivalent volume of DMSO. An immunoblot of cell lysates for NLRP3, ASC, procaspase-1 and proIL-1β is shown on the top, and densitometry data is shown on the bottom. Data is expressed in arbitrary units as well as fold-induction of each experiment with sorted-cells pooled from 60 colons for each experiment. Representative data of three independent experiments showing similar results. (**b**) Immunobotting for NLRP3 and proIL-1β protein was performed on cell lysates from F4/80$^+$/CD64$^+$ cMPs from IL-10$^{-/-}$ or WT mice (left panel), or from WT mice treated with anti-IL-10R antibodies or isotype control for 11 days (middle panel) and from F4/80$^+$/CD64$^+$Ly6C$^{lo/-}$ cMPs from WT/ IL-10RB$^{-/-}$ mixed chimeric mice (right panel). (**c**) mRNA levels for NLRP3 and proIL-1β from cMPs from IL-10$^{-/-}$ or WT mice (upper panel), or from WT mice treated with anti-IL-10R antibodies or isotype control for 11 days (bottom panel). Data from a single experiment with sorted-cells pooled form 30 colons from IL-10$^{-/-}$ or WT mice, and representative data of two independent experiments showing similar results with sorted-cells pooled from 30 colons from anti-IL-10R or WT mice, or 100 colons from mixed BM chimeric mice is shown.